Canine tracheobronchial disease

Author(s):  
Lynelle R. Johnson ◽  
Brendan C. McKiernan
2009 ◽  
Vol 123 (12) ◽  
pp. 1375-1377 ◽  
Author(s):  
J E Peters ◽  
A D Salama ◽  
P W Ind

AbstractObjective:We report a patient with a 20-year history of apparently idiopathic airways stenoses, who presented with an antineutrophil cytoplasmic antibody (ANCA) associated, acute, systemic vasculitis with necrotising glomerulonephritis, subsequently diagnosed as Wegener's granulomatosis.Methods:We present a case report and a review of the world literature on airway stenosis in Wegener's granulomatosis.Results:To our knowledge, this is the first report of Wegener's granulomatosis manifesting as local airway disease for such a prolonged period, before transforming into a systemic vasculitis.Conclusions:This case highlights the need for physicians to be alert to the possibility of Wegener's granulomatosis as a cause of apparently idiopathic airway stenosis, and to be aware that systemic disease may occur in very long-standing, limited Wegener's granulomatosis.


CHEST Journal ◽  
2001 ◽  
Vol 120 (1) ◽  
pp. 43-49 ◽  
Author(s):  
Hubert Hautmann ◽  
Fernando Gamarra ◽  
Klaus Jürgen Pfeifer ◽  
Rudolf Maria Huber

2000 ◽  
Vol 7 (2) ◽  
pp. 184-187 ◽  
Author(s):  
Alicia N. Rodriguez ◽  
José P. Díaz-Jiménez ◽  
Eric S. Edell

2014 ◽  
Vol 26 (1) ◽  
pp. 71-75 ◽  
Author(s):  
Adnan Mohamad Al-Ayoubi ◽  
Faiz Yahya Bhora

2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
M Zammit ◽  
S Hardy ◽  
J Harper ◽  
A Panarese ◽  
C Webb

Abstract Introduction Subglottic stenosis (SGS) is the commonest manifestation of tracheobronchial disease in granulomatosis with polyangiitis (GPA) and carries a high degree of morbidity. Management of SGS-GPA is a double-edged sword. Delayed treatment may cause respiratory compromise and infectious complications. However, aggressive surgical management may initiate a systemic inflammatory response, reactivating the vasculitic cascade and potentially lead to long-term complications including renal vasculitis and consequential end-stage renal failure. There is currently no internationally agreed management strategy for this disease. Method This retrospective review was undertaken to analyse our unique combination of surgical dilatations and immunosuppressive-focused adjuvant management strategy between years 2011-2020. Results Sixteen of our one hundred and nine GPA patients (14.7%) had SGS and were included in our analysis. Whilst three patients (18.8%) improved solely on medical treatment, thirteen (81.3%) required combined surgery and immunosuppression (consisting of cyclophosphamide or Rituximab regimens). Thirty-nine surgical dilatations and two tracheostomies were performed over a mean 53-month follow-up period, with a calculated mean procedure rate of one every 24.8 months (2.7 - 89 months). Conclusions Our current management strategy affords a lower procedure rate at every 24.8 months compared to other published studies with combined procedure rate at every 14.9 months.


Sign in / Sign up

Export Citation Format

Share Document